Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.
